All research in AI Pharmaceuticals (AI Drug Discovery) — 1 reports.
Recursion Pharmaceuticals (RXRX.US) is the flagship AI drug-discovery name: the largest and most broadly integrated AI-native drug company globally, with Exscientia added in 2024 to fill the precision-chemistry gap. The core thesis is a hybrid of an AI drug-discovery platform and an in-house biotech pipeline, backed by deep partnerships with NVIDIA, Roche/Genentech, Bayer, Sanofi, and others, yet still dependent on unpredictable collaboration milestones with no product revenue. Report rating Watch: real infrastructure assets and a heavily reset valuation deserve close tracking, but NVIDIA exited its stake by the end of 2025 and founder CEO Chris Gibson has stepped down while the platform remains clinically unproven.
